The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has dramatically improved over the last decade; however, patients with visceral metastases are still faced with poor outcomes. Phosphatase and tensin homolog (PTEN) loss is observed in 40%–60% of mCRPC patients and is also associated with a poor prognosis. Several PI3K/AKT/mTOR pathway inhibitors have been studied, with disappointing anti-tumor activity. Here, we present a case of a patient with heavily treated mCRPC who had a modest tumor response to concurrent carboplatin, abiraterone acetate/prednisone, and liver-directed radiation therapy. We discuss the potential rationale supporting the use of this combination therapy and its safety in mCRPC. While the underlying basic mechanism of our patient’s anti-tumor response remains uncertain, we suggest that further prospective studies are warranted to evaluate whether this combination therapy is effective in this population of patients with pre-treated mCRPC and PTEN loss.
Digital Object Identifier (DOI)
This funding is supporting the University of Kentucky Markey Cancer Center’s Research Communications Office. They assisted with preparation of this manuscript.
Myint, Zin W.; Allison, Derek B.; and Ellis, Carleton S., "A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss" (2021). Internal Medicine Faculty Publications. 261.